echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The legendary creature CAR-T sells well in Europe and the United States! Domestic CAR-T is still involutional! "Going to sea" through the winter?

    The legendary creature CAR-T sells well in Europe and the United States! Domestic CAR-T is still involutional! "Going to sea" through the winter?

    • Last Update: 2022-11-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    GenScript Biotechnology recently announced that Legend Biologics' cell therapy CARVYKTI (Cedakiolence) achieved net sales of 55 million US dollars in the third quarter of this year, doubling from 24 million in the second quarter, and the total sales of the two quarters were about 570 million yuan, exceeding market expectations
    Cedarquiolensis once again demonstrates strong market potential

    Cedakiolensel was approved by the US Food and Drug Administration (FDA) on February 28 this year, becoming the first cell therapy independently developed in China and approved overseas for the treatment of adult patients
    with relapsed or refractory multiple myeloma who have received 4 or more previous therapies.
    Since then, it has obtained conditional marketing authorization from the European Commission (EC) on May 26, and was approved by the Ministry of Health, Labor and Welfare on September 27, and is about to apply for listing
    in Japan.

    The successful approval and commercialization of the legendary biologics cedarquiolensis in the United States has opened the precedent for domestic innovative biopharmaceuticals to go overseas in Europe and the United States, and also highlighted the clinical value and market value
    of differentiated innovative products.

    "At present, domestic cell therapy is gradually showing an involution dilemma!" Industry experts pointed out that the domestic CAR-T therapy research and development targets are too concentrated and the commercialization cycle is long; At the same time, although CAR-T therapy has made gratifying progress in the treatment of hematological malignancies, it still faces many challenges
    in the treatment of solid tumors.

    Differentiation and innovation and overseas listing have become a new way
    out for pharmaceutical companies on the CAR-T track.
    The legendary bio Cedarquiolensis has been listed and sold well overseas, which not only provides domestic pharmaceutical companies with ideas for products to go abroad, but also encourages domestic pharmaceutical companies to participate in global competition
    in the CAR-T field.

    There is a way out for global commercialization

    There is a way out for global commercialization

    How can innovative products "go to sea"?

    How can innovative products "go to sea"?

    As an emerging therapy, CAR-T therapy has developed hotly in the past few years, concentrated on the market, and has become the focus
    of capital attention.

    September 2017 Targeting CD19

    September 2017

    The world's first CAR-T therapy, Kymirah, was approved for the treatment of patients
    under 25 years of age with relapsed or refractory B-cell acute lymphoblastic leukemia.

    October 2017 Targeting CD19

    October 2017

    The FDA approved Gilead's Yescarta for the treatment of
    adult patients with relapsed or refractory large B-cell lymphoma (LBCL) who have previously received second- or multi-line systemic therapy.

    March 2021 Targeting BCMA

    March 2021

    Abecma, jointly developed by BMS and Bluebird Biologics, is approved by the FDA for the treatment of adult patients
    with relapsed/refractory multiple myeloma (R/R MM).

    June 2021 Targeting CD19

    June 2021

    China's first cell therapy product, Fosun Kate's CAR-T product aquilencepta, has been approved by the State Food and Drug Administration for the treatment of relapsed and refractory large B-cell lymphoma
    in adults.

    September 2021 Targeting CD19

    September 2021

    JW Therapeutics is approved by the NMPA for the treatment of relapsed or refractory large B-cell lymphoma (r/r LBCL)
    in adults following second-line or more systemic therapy.

    At present, it has been approved for marketing CAR-T therapy, mostly CD19 targets
    Looking back at the development of cell therapy in the field of hematologic tumor treatment, although cedarquiolensis is not the first BCMA approved for marketing in the world CAR-T therapy, but in terms of clinical benefits, cedarquiolensis is also worth looking forward to

    In the pivotal CARTITUDE-1 study, the overall response rate ORR/complete response rate(s)CR of 98%/78% for the primary endpoint of cedarquiolensis compared with 72%/39% for Abecma, with cedarquiolensis having a clear advantage
    In addition, median progression-free survival for mPFS is more than 2 years, which is higher than the average of 8 to 12 months
    for comparable therapies.

    In the context of the complex international political and economic environment, Legend Biologics can also achieve the approval of its self-developed products in the US FDA, in the final analysis, its products are the best in class, and the safety, efficacy and other data have significant advantages
    over the marketed products.

    According to the clinical development plan announced by Legend Biologics on the R&D day last October, clinical trials
    for more front-line treatments will be carried out in the future.

    Cilta-cel Multiple Myeloma Development Program

    In December 2017, Legend Biologics entered into an exclusive global licensing and collaboration agreement with Johnson & Johnson to jointly develop and commercialize cedarquiolence.

    The deal alone was an upfront payment of $350 million, one of the highest
    domestic license-out authorizations at the time.
    Under the agreement, Legend Bio and Johnson & Johnson have a 50/50
    cost and profit split in the global market.
    Since then, the two companies have worked together to advance the development of

    According to the 50% sharing clause with Johnson & Johnson, Cedarqui Olencel achieved revenue of nearly 300 million yuan in the first two quarters after its overseas listing

    In the U.
    , Novartis' Kymriah, Gilead's Yescarta, and Legendary Biologics' Carvykti are priced at $475,000, $373,000, and $465,000, respectively, with sales of $587 million and $695 million
    , respectively, in 2021.

    In contrast, in China, Fosun Kite's Yikaida and JW Therapeutics' Carteyeta, which were listed in 2021, were priced at RMB1.
    2 million per needle and RMB1.
    29 million/needle respectively, achieving sales of about RMB100 million and RMB30.
    797 million respectively
    that year.
    In the first half of 2022, JW Therapeutics issued 77 Carteta prescriptions, achieving sales revenue of about 66 million yuan
    In contrast, the overseas market sales of CAR-T products far exceed those in China

    The R&D side is limited on the payment side

    The R&D side is limited on the payment side

    Domestic CAR-T commercialization is difficult

    Domestic CAR-T commercialization is difficult

    As the darling of anti-cancer therapy in recent years, the effectiveness of CAR-T therapy has been verified one after another, from clinical research and development to commercialization
    According to Sullivan's analysis, it is predicted that the global CAR-T therapy market size will reach $21.
    8 billion
    by 2030.

    The market potential is huge, and many domestic cell therapy companies have also followed suit and actively deployed the CAR-T market
    At present, two CAR-T therapies
    targeting CD19 have been approved in China, Fosun Kite and JW Therapeutics.

    In addition, according to industry statistics, there are more than ten clinical trials of CAR-T cell therapy products targeting CD19 in progress

    In addition to the popular CD19 targets, the competition of CAR-T cell therapy products targeting BCMA should not be

    On October 18, CARsgen announced that its new drug application (NDA) for its fully human anti-autologous CAR-T product Zevokiolencel has been accepted by CDE for relapsed or refractory multiple myeloma (R/R) that has previously failed treatment with at least one immunomodulator and proteasome inhibitor MM) adult patients
    This is also the second BCMA CAR-T product
    to be declared for marketing in China after Innovent Biologics/Reindeer Medical's Iquilenca injection in June this year.

    At present, there are 2 CAR-T cell therapy products targeting BCMA on the market
    In China, in addition to the above 2 BCMA-targeting CAR-T cell therapy products have been submitted to NDA, there are also 4 BCMA-targeting CAR-T clinical trial projects registered on the CDE drug clinical trial registration and information disclosure platform

    According to statistics from the New Media Center of Pharmaceutical Economic News, the NMPA has received more than 27 marketing applications for CAR-T therapies, including Fosun Kite, JW Therapeutics, Keji Pharmaceutical, Innovent Biologics/Reindeer Medical, Ganxi Biologics, Yongtai Biologics, Legend Biologics, etc

    In order to compete for the market opportunity of CAR-T therapy, various pharmaceutical companies do not hesitate to invest heavily in research and development, which is very similar to the situation of PD-1, and the market competition will become more and more fierce
    in the future.

    Unlike other innovative drugs, the cost of CAR-T products does not actually depend on the company itself
    At present, the domestic listed CAR-T products are more expensive, mainly because they require personalized preparation, more expensive imported carriers and other materials, and the amount of product preparation is too small to form a scale effect
    Even though the current purchase price of JW Therapeutics' relma-cel injection is 1.
    29 million yuan / needle, and Fosun Kate's aquilencel injection is 1.
    2 million yuan / needle, the profit margin is still very thin
    for enterprises.

    JW Therapeutics lost 700 million yuan in 2021, relma-cel sales of 30.
    797 million yuan, sales costs as high as 21.
    752 million yuan, gross profit of 9.
    045 million yuan, gross profit margin of only 29.
    4%, including R&D, management and other expenses, instantly broke through the cost line

    Although in the 2022 half-year report, JW Therapeutics stated that its gross profit margin in the first half of the year had risen to 35.
    0% through the implementation of the cost reduction plan, only 77 prescriptions
    were issued in the first half of the year.

    "Drug discovery and commercialization are two logics
    " The market view is that many good products developed in clinical practice have not achieved good commercial results in the end, and CAR-T is facing the same test

    If you can enter medical insurance, it is obviously the most direct way to
    solve the market accessibility of innovative products and improve the coverage of commercial terminals of products.
    However, China's basic medical insurance has the characteristics of wide coverage and low security, unless the price is actively reduced, it is impossible for medical insurance to pay for drugs exceeding one million yuan a shot in the short term

    In fact, it is not easy
    for CAR-T products to obtain medical insurance support and obtain a broader space through medical insurance negotiations.
    In July this year, the official WeChat account of China Medical Insurance, a magazine under the supervision of the National Medical Insurance Bureau, published articles entitled "Misunderstandings in Discussing the Pricing of Drugs for Rare Diseases" and "Several Suggestions on the Protection of Drugs for Rare Diseases in China", which directly pointed to the phenomena
    of "high sales costs", "avoiding medical insurance welfare", "inflated drug prices" and "stubborn diseases".

    Compared with the legendary creatures that conquered the US market, while the price is higher, it also gains more patients; The domestic CAR-T product research and development end is limited in volume and payment, and commercialization is difficult

    Industry insiders predict that with the enhancement of domestic innovation strength, the increasingly fierce competition in the domestic market, and the attractiveness of the overseas innovative drug market, more and more Chinese innovative drugs will choose to go overseas and actively embrace international competition
    in the future.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.